of Gemtuzumab Ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed de novo AML patients aged 50-70 years old: A prospective randomized Phase 3 trial from the Acute Leukemia French Association (ALFA).
Initial Data Show That Fractionated Doses
of Actimab-A in Combination with LDAC are Safe and Have Antileukemic Activity in Older Patients with Acute Myeloid Leukemia
Phase 3 data showing that fractionated doses
of gemtuzumab ozogamicin combined with standard chemotherapy improves survival in AML patients aged 50-70.
The radio labeled form of epratuzumab (90Y-DOTA-epratuzumab) is being studied in a Phase I/II dose-escalation trial in Europe, involving fractionated doses
of 90Y-DOTA-epratuzumab given over 2 or 3 weeks, and presented as an interim report in Poster 2545 with Professor J.
1479 and 1482) describe that fractionated doses
of radiolabeled epratuzumab (90Y-epratuzumab) can be administered safely to both indolent and aggressive NHL patients with only minimal toxicity, and can result in durable objective responses in patients with various subtypes of NHL, including those with mantle cell lymphoma.